US 11,866,705 B2
Small cell lung cancer therapeutic agent containing oligonucleotide
Masahito Shimojo, Osaka (JP); Satoshi Obika, Osaka (JP); Yuya Kasahara, Osaka (JP); Takao Suzuki, Osaka (JP); Masaki Yamagami, Osaka (JP); and Tadashi Umemoto, Osaka (JP)
Assigned to Osaka Univerity, Osaka (JP); National Institutes of Biomedical Innovation, Health and Nutrition, Osaka (JP); and Luxna Biotech Co., Ltd., Osaka (JP)
Appl. No. 17/261,653
Filed by Osaka University, Osaka (JP); National Institutes of Biomedical Innovation, Health and Nutrition, Osaka (JP); and Luxna Biotech Co., Ltd., Osaka (JP)
PCT Filed Jul. 31, 2019, PCT No. PCT/JP2019/030090
§ 371(c)(1), (2) Date Jan. 20, 2021,
PCT Pub. No. WO2020/027227, PCT Pub. Date Feb. 6, 2020.
Claims priority of application No. 2018-144016 (JP), filed on Jul. 31, 2018.
Prior Publication US 2021/0277398 A1, Sep. 9, 2021
Int. Cl. C12N 15/113 (2010.01)
CPC C12N 15/113 (2013.01) [C12N 2310/11 (2013.01); C12N 2310/3231 (2013.01)] 4 Claims
OG exemplary drawing
 
4. An oligonucleotide or a pharmacologically acceptable salt thereof, wherein the oligonucleotide is:
hnSR100-7170-LNA(19) (SEQ ID No. 124),
hnSR100-7168-LNA(19) (SEQ ID No. 127),
hnSR100-7166-LNA(19) (SEQ ID No. 130),
hnSR100-7172-LNA(19) (SEQ ID No. 133),
hnSR100-7170-AmNA(19) (SEQ ID No. 154),
hnSR100-7168-AmNA(19) (SEQ ID No. 157), or
hnSR100-7172-AmNA(19) (SEQ ID No. 163).